Drug Interaction Report

Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atogepant, which is primarily metabolized by the isoenzyme. When atogepant was administered in healthy study subjects with steady-state rifampin, a potent CYP450 3A4 inducer, atogepant peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 30% and 60%, respectively. No dedicated drug interaction studies were conducted to assess concomitant use with moderate or weak CYP450 3A4 inducers. While moderate inducers can likely decrease atogepant exposure, clinically significant interaction is not expected with concomitant administration of weak inducers. No dosage adjustment of atogepant is needed when used with weak CYP450 3A4 inducers.

MONITOR: Isolated case reports have suggested that the ingestion of alcohol during griseofulvin therapy may rarely cause disulfiram-like reactions, flushing, tachycardia, or increased effects of alcohol. The mechanism is unknown.

MANAGEMENT: Patients should be advised of the possibility of increased adverse effects or a disulfiram-like reaction.